Insulet Corporation (NASDAQ:PODD) Sees Significant Growth in Short Interest

Insulet Corporation (NASDAQ:PODD) saw a significant growth in short interest during the month of February. As of February 27th, there was short interest totaling 2,817,783 shares, a growth of 86.4% from the February 12th total of 1,511,612 shares. Based on an average daily trading volume, of 1,172,256 shares, the short-interest ratio is presently 2.4 days. Approximately 4.0% of the company’s stock are short sold. Approximately 4.0% of the company’s stock are short sold. Based on an average daily trading volume, of 1,172,256 shares, the short-interest ratio is presently 2.4 days.

Insider Activity

In related news, Director Michael R. Minogue acquired 2,030 shares of the stock in a transaction dated Wednesday, February 25th. The shares were acquired at an average price of $246.23 per share, with a total value of $499,846.90. Following the acquisition, the director owned 17,483 shares in the company, valued at approximately $4,304,839.09. The trade was a 13.14% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.39% of the company’s stock.

Institutional Investors Weigh In On Insulet

Several large investors have recently modified their holdings of PODD. Vanguard Group Inc. boosted its stake in shares of Insulet by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 8,796,200 shares of the medical instruments supplier’s stock valued at $2,715,651,000 after purchasing an additional 87,845 shares in the last quarter. State Street Corp increased its holdings in shares of Insulet by 2.1% during the fourth quarter. State Street Corp now owns 3,155,489 shares of the medical instruments supplier’s stock worth $896,916,000 after buying an additional 65,317 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Insulet by 2.1% in the fourth quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier’s stock valued at $568,274,000 after acquiring an additional 41,019 shares during the last quarter. Invesco Ltd. raised its stake in shares of Insulet by 10.5% in the fourth quarter. Invesco Ltd. now owns 1,480,562 shares of the medical instruments supplier’s stock valued at $420,835,000 after acquiring an additional 141,167 shares during the last quarter. Finally, Norges Bank acquired a new position in shares of Insulet in the 4th quarter worth approximately $300,794,000.

Wall Street Analyst Weigh In

PODD has been the topic of several research analyst reports. Royal Bank Of Canada raised their price objective on shares of Insulet from $370.00 to $380.00 and gave the stock an “outperform” rating in a research note on Friday, November 21st. Sanford C. Bernstein cut their target price on shares of Insulet from $380.00 to $330.00 and set an “outperform” rating for the company in a research note on Thursday, February 19th. TD Cowen downgraded shares of Insulet from a “buy” rating to a “hold” rating and set a $294.00 price target for the company. in a report on Monday, January 26th. Leerink Partners decreased their price target on shares of Insulet from $386.00 to $360.00 and set an “outperform” rating on the stock in a research report on Thursday, February 19th. Finally, Raymond James Financial dropped their price objective on shares of Insulet from $385.00 to $355.00 and set an “outperform” rating on the stock in a report on Thursday, February 19th. Twenty research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $354.24.

Key Headlines Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Study results support long‑term product thesis: new study outcomes backing a fully closed‑loop insulin pump for type 2 diabetes could reinforce Insulet’s growth runway if commercial adoption follows. Study Outcomes
• Neutral Sentiment: Company says affected supply is limited and replacement capacity exists — Insulet initiated a voluntary medical device correction and communicated it publicly, and management stated they expect to replace impacted Pods without disrupting overall availability. Investors should watch follow‑up disclosures for replacement costs and execution risk. Company Correction
• Negative Sentiment: Recall / Medical device correction highlights manufacturing defect — Regulators and media report specific U.S. lots of Omnipod 5 Pods were recalled/subject to correction because of potential tubing tears that could under‑deliver insulin, increasing short‑term revenue and reputation risk. Reuters Recall
• Negative Sentiment: Safety reports and potential patient harm amplified selling — Insulet disclosed multiple serious adverse event reports (including hospitalizations and DKA tied to under‑delivery) which raises regulatory/legal exposure and hurts investor confidence. Seeking Alpha Recall
• Negative Sentiment: Multiple securities‑fraud investigations and law‑firm notices have been announced — several firms are soliciting claimants alleging the company may have misled investors about the issue, creating potential litigation risk and additional headline pressure. Fraud Investigation
• Negative Sentiment: Market coverage and technicals: the headlines drove the stock to a 52‑week low and broader market writeups (MSN/Benzinga) are amplifying downward momentum. Expect short‑term analyst and sentiment reactions until clarity on scope, costs and regulatory response. 52‑Week Low

Insulet Stock Performance

PODD traded down $16.23 during trading on Friday, reaching $219.84. 2,117,007 shares of the company’s stock were exchanged, compared to its average volume of 1,078,540. The company has a market capitalization of $15.48 billion, a P/E ratio of 62.81, a PEG ratio of 1.41 and a beta of 1.42. The company has a quick ratio of 2.15, a current ratio of 2.81 and a debt-to-equity ratio of 0.61. The business has a 50 day moving average price of $258.47 and a 200 day moving average price of $297.31. Insulet has a fifty-two week low of $216.49 and a fifty-two week high of $354.88.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.48 by $0.07. Insulet had a net margin of 9.12% and a return on equity of 24.90%. The company had revenue of $783.80 million during the quarter, compared to analysts’ expectations of $768.31 million. During the same quarter in the prior year, the company posted $1.15 EPS. The business’s revenue was up 31.2% on a year-over-year basis. As a group, analysts predict that Insulet will post 3.92 earnings per share for the current fiscal year.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.